SG11202110413YA - Method for preparing stable peptide formulations - Google Patents

Method for preparing stable peptide formulations

Info

Publication number
SG11202110413YA
SG11202110413YA SG11202110413YA SG11202110413YA SG11202110413YA SG 11202110413Y A SG11202110413Y A SG 11202110413YA SG 11202110413Y A SG11202110413Y A SG 11202110413YA SG 11202110413Y A SG11202110413Y A SG 11202110413YA SG 11202110413Y A SG11202110413Y A SG 11202110413YA
Authority
SG
Singapore
Prior art keywords
preparing stable
peptide formulations
stable peptide
formulations
preparing
Prior art date
Application number
SG11202110413YA
Inventor
Gregory Nelson Brown
Scoik Kurt Gard Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202110413YA publication Critical patent/SG11202110413YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11202110413YA 2019-04-26 2020-04-20 Method for preparing stable peptide formulations SG11202110413YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839246P 2019-04-26 2019-04-26
PCT/US2020/028988 WO2020219391A1 (en) 2019-04-26 2020-04-20 Method for preparing stable peptide formulations

Publications (1)

Publication Number Publication Date
SG11202110413YA true SG11202110413YA (en) 2021-10-28

Family

ID=70554273

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110413YA SG11202110413YA (en) 2019-04-26 2020-04-20 Method for preparing stable peptide formulations

Country Status (20)

Country Link
US (1) US20220192988A1 (en)
EP (1) EP3958838A1 (en)
JP (2) JP7245926B2 (en)
KR (1) KR20210143253A (en)
CN (1) CN113727700A (en)
AR (1) AR118690A1 (en)
AU (1) AU2020261941B2 (en)
BR (1) BR112021018325A2 (en)
CA (1) CA3134757A1 (en)
CL (1) CL2021002690A1 (en)
CO (1) CO2021014034A2 (en)
EA (1) EA202192475A1 (en)
EC (1) ECSP21079422A (en)
IL (1) IL286426A (en)
MA (1) MA55757A (en)
MX (1) MX2021012852A (en)
PE (1) PE20212368A1 (en)
SG (1) SG11202110413YA (en)
TW (1) TWI771669B (en)
WO (1) WO2020219391A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718762A (en) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 Polypeptide sample stabilizer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK49791D0 (en) * 1991-03-20 1991-03-20 Novo Nordisk As NASAL POWDER PREPARATION
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
PL2370462T3 (en) 2008-12-15 2015-01-30 Zealand Pharma As Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
CN102292347A (en) 2008-12-15 2011-12-21 西兰制药公司 Glucagon analogues
SI2454282T1 (en) 2009-07-13 2015-06-30 Zealand Pharma A/S Acylated glucagon analogues
JP2013523620A (en) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー/エス New glucagon analog
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
KR20130086343A (en) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 Glucagon analogues
CA2839867A1 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Ski-to-mono bond
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
US9018162B2 (en) * 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CR20170373A (en) * 2015-02-17 2017-09-18 Lilly Co Eli NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLIGEMIA

Also Published As

Publication number Publication date
JP2023075249A (en) 2023-05-30
ECSP21079422A (en) 2021-11-30
EA202192475A1 (en) 2022-01-28
PE20212368A1 (en) 2021-12-21
US20220192988A1 (en) 2022-06-23
AU2020261941B2 (en) 2023-04-06
AU2020261941A1 (en) 2021-10-14
KR20210143253A (en) 2021-11-26
CL2021002690A1 (en) 2022-07-08
JP7245926B2 (en) 2023-03-24
CA3134757A1 (en) 2020-10-29
MA55757A (en) 2022-03-02
JP2022529614A (en) 2022-06-23
TW202108599A (en) 2021-03-01
MX2021012852A (en) 2021-12-10
TWI771669B (en) 2022-07-21
AR118690A1 (en) 2021-10-27
EP3958838A1 (en) 2022-03-02
BR112021018325A2 (en) 2021-11-23
CO2021014034A2 (en) 2021-10-29
IL286426A (en) 2021-10-31
CN113727700A (en) 2021-11-30
WO2020219391A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
SG11202109277WA (en) Stable protein formulations
IL277797A (en) Methods for making stable protein compositions
IL287224A (en) Novel formulations comprising melflufen
IL283331A (en) Method for preparing n-phenylpyrazole-1-carboxamides
EP3804853A4 (en) Preparation method for s-indoxacarb
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
IL285674A (en) Pharmaceutical formulations
IL286024A (en) Stabilized formulations containing anti-il-33 antibodies
GB201904338D0 (en) Fluorouracil-containing formulations
IL286426A (en) Method for preparing stable peptide formulations
PT4045038T (en) New formulations
GB2580226B (en) Formulations for hair growth
GB201909178D0 (en) Methods for preparing compounds
IL290356A (en) Larazotide formulations
IL284691A (en) Formulations
IL282108A (en) Preparation method for efinaconazole
FI3781132T3 (en) Apixaban formulations
GB201911063D0 (en) Formulations
GB201905105D0 (en) Formulations
SG11202106305PA (en) Method for synthesizing peptides
EP4074332A4 (en) Method for preparing peptide emulsion formulation
GB201910093D0 (en) New formulations
GB201910092D0 (en) New formulations
EP3835313A4 (en) Method for preparing gly-t?4
PT3651736T (en) Long-acting formulations